News & Updates
Showing Oncology articles
Showing
Second cancers may develop in women with early invasive breast cancer
Women treated for early invasive breast cancer have a slightly higher risk of a second primary cancer than those in the general population, reveals a study. Such risk is greater among younger women.
First-line durvalumab plus tremelimumab safe to use in unresectable HCC
The phase IIIb SIERRA study has shown an acceptable safety profile for the single tremelimumab regular interval durvalumab (STRIDE) regimen as first-line treatment for patients with hepatocellular carcinoma (HCC) who have a poor prognosis.
Supplemental imaging strategies facilitate early cancer detection in women with dense breasts
Supplemental breast cancer (BC) imaging techniques may help detect early cancers that standard mammograms may have missed in women with dense breasts, according to interim results from the BRAID* trial.
Durvalumab plus FLOT improves event-free survival in gastric, GEJ adenocarcinoma
Patients with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma demonstrate significant improvements in event-free survival (EFS) following treatment with durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy compared with placebo plus FLOT, as shown by the results of the phase III MATTERHORN study.
Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer
The addition of relacorilant to nab-paclitaxel provides survival benefits in patients with platinum-resistant ovarian cancer (PROC) compared with weekly taxane, according to the results of the phase III ROSELLA study, presented at ESMO Gyn 2025.